Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
TPR
REST API REST API
Homo sapiens
TPR is differentially expressed in 323 experiments: 150 organism parts: bone marrow, testis, ... (148 more);, 245 disease states: normal, acute myeloid leukemia, ... (243 more);, 101 cell types 428 cell lines 39 compound treatments and 72 other conditions.
Orthologs TPR (Bos taurus)   ENSCING00000001169 (Ciona intestinalis)   Tpr (Mus musculus)   TPR (Gallus gallus)   tprb (Danio rerio)   MLP2 (Saccharomyces cerevisiae)   tpra (Danio rerio)   Tpr (Rattus norvegicus)   MLP1 (Saccharomyces cerevisiae)   Mtor (Drosophila melanogaster)   tpr (Xenopus laevis)   TPR (Canis familiaris)   (Compare orthologs)
Gene Ontology Term serine-tRNA ligase activity, protein binding, kinetochore, cytoplasm, mRNA transport, protein import into nucleus, membrane, condensed chromosome kinetochore, ATP binding, nucleus, nucleotide binding, carbohydrate metabolic process, nuclear envelope, nuclear pore, chromosome, transmembrane transport, nucleoplasm, seryl-tRNA aminoacylation, mitotic cell cycle spindle assembly checkpoint, protein transport, nuclear membrane, viral reproduction, glucose transport, regulation of glucose transport, hexose transport
InterPro Term TPR_MLP1_2
UniProt Accession Q9UE33, P12270, Q5SWX9
Gene-Disease Assocation THYROID CARCINOMA, PAPILLARY
Search EB-eye ENSG00000047410
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-6573, E-GEOD-1577, E-GEOD-3526, E-MTAB-62, ... (26 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, ... (43 experiments)

Factor Value U/D Experiments
BT474
3
E-MEXP-440, E-MTAB-62, E-MTAB-37
K562
3
E-MTAB-37, E-GEOD-96, E-GEOD-24147
MCF-7
3
E-GEOD-19639, E-GEOD-3529, E-GEOD-20081
SW480
3
E-MEXP-1014, E-GEOD-18005, E-MTAB-37
primary culture
2
E-GEOD-1657, E-GEOD-2450
AGS
2
E-GEOD-15460, E-MTAB-37
422 more value(s).


Cell type

studied in E-GEOD-22529, E-GEOD-3920, E-MEXP-750, E-GEOD-4219, E-GEOD-13909, ... (45 experiments)

Factor Value U/D Experiments
fibroblast
2
E-GEOD-3920, E-GEOD-26672
hematopoietic stem cell
1
E-MEXP-1403
activated natural killer cell
1
E-TABM-702
CD3- CD56bright CD62L+ NK cell
1
E-GEOD-21774
germ cell
1
E-MTAB-25
unstimulated polymorphonuclear leukocyte
1
E-GEOD-935
95 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-1577, E-MEXP-2280, E-GEOD-4060, ... (69 experiments)

Factor Value U/D Experiments
prostate carcinoma
3
E-GEOD-96, E-MEXP-2034, E-MTAB-62
rhabdomyosarcoma
2
E-MTAB-62, E-MTAB-37
extranodal NK/T-cell lymphoma
2
E-TABM-702, E-GEOD-19067
melanoma
2
E-MTAB-37, E-MTAB-62
osteosarcoma
2
E-MTAB-37, E-MTAB-62
cervical carcinoma
2
E-MTAB-62, E-MTAB-37
239 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5258, E-GEOD-1417, E-TABM-782, E-GEOD-3720, ... (27 experiments)

Factor Value U/D Experiments
lipopolysaccharide
2
E-MEXP-1958, E-TABM-868
Emdogain
1
1
E-MEXP-2645
TNF
1
1
E-GEOD-15205
sapphyrin PCI-2050
1
E-GEOD-6400
nebivolol
1
E-GEOD-3356
vanadium pentoxide
1
E-GEOD-5339
33 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519


Biosource provider
studied in E-GEOD-14359, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (11 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-17189, E-GEOD-6710, E-MEXP-1251, ... (12 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

crosslinker and crosslinking wavelength
studied in E-GEOD-21918

Developmental stage
studied in E-GEOD-19743, E-GEOD-3140, E-MEXP-2359, E-GEOD-2666, E-GEOD-4667, ... (7 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-7788, E-GEOD-3325, E-MEXP-2280, E-TABM-147, ... (7 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-4025, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847 ... (5 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-17476, E-GEOD-21750, E-TABM-321, E-TABM-43, ... (8 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-7011, E-GEOD-22278, E-GEOD-10315, E-MEXP-1273, ... (14 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-TABM-325, E-MTAB-197, E-MEXP-2069, E-GEOD-1926, E-TABM-15, ... (41 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, ... (6 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

Organism
studied in E-GEOD-1801, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Phenotype
studied in E-GEOD-22309, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460, E-GEOD-17636 ... (5 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

Replicate
studied in E-GEOD-18791

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-MEXP-548, ... (7 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

Sampling time point
studied in E-GEOD-19743, E-MEXP-70

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-19743, E-GEOD-22541, E-GEOD-7307, E-GEOD-1295

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-TABM-125

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-22369, E-GEOD-33562, E-GEOD-22368, E-GEOD-16837, E-GEOD-19246, ... (6 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4922, E-TABM-147

Vehicle
studied in E-GEOD-5258

Processing time: 0.264 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM